Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22363310 | 0.86 | MEN1 (0.33) | DDB1CRBNIDH1KDM4E | |
| SCHEMBL22363278 | 0.83 | MAPT (0.37) | DDB1CRBNIDH1HCRTR1CYP1A2 | |
| SCHEMBL22363307 | 0.83 | DDB1 (0.35) | DDB1CRBN | |
| SCHEMBL20580193 | 0.81 | FPR2 (0.40) | KDM4E | |
| SCHEMBL20580195 | 0.81 | FPR2 (0.40) | KDM4E | |
| SCHEMBL22363273 | 0.80 | DDB1 (0.37) | DDB1CRBNIDH1 | |
| SCHEMBL21024547 | 0.80 | KDM4E (0.38) | ALOX5APKDM4ELMNA | |
| SCHEMBL22363279 | 0.79 | DDB1 (0.36) | DDB1CRBNIDH1LMNA | |
| SCHEMBL20580036 | 0.79 | DDB1 (0.35) | DDB1CRBNIDH1KDM4ELMNA | |
| SCHEMBL20098229 | 0.78 | CBLB (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | DDB1 4468/4885CRBN 1203/4885IDH1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.